$1.53
1.29% day before yesterday
Nasdaq, Aug 22, 10:00 pm CET
ISIN
NL0015000AG6
Symbol
LVTX

LAVA Therapeutics NV Stock price

$1.53
+0.09 6.25% 1M
+0.59 62.77% 6M
+0.58 60.88% YTD
-0.34 18.18% 1Y
-0.98 39.04% 3Y
-13.47 89.80% 5Y
-13.47 89.80% 10Y
-13.47 89.80% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
-0.02 1.29%
ISIN
NL0015000AG6
Symbol
LVTX
Industry

Key metrics

Basic
Market capitalization
$40.3m
Enterprise Value
$-26.3m
Net debt
positive
Cash
$66.6m
Shares outstanding
26.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.4 | -
EV/Sales
negative | -
EV/FCF
2.5
P/B
1.6
Financial Health
Equity Ratio
34.6%
Return on Equity
-89.7%
ROCE
-95.3%
ROIC
-4,167.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$12.0m | $0.0
EBITDA
$-58.1m | $-33.3m
EBIT
$-57.9m | $-29.6m
Net Income
$-49.2m | $-30.7m
Free Cash Flow
$-10.5m
Growth (TTM | estimate)
Revenue
-4.5% | -100.0%
EBITDA
-90.6% | -13.8%
EBIT
-82.9% | 0.3%
Net Income
-72.1% | -22.2%
Free Cash Flow
66.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-484.6% | -
EBIT
-483.5%
Net
-410.5% | -
Free Cash Flow
-87.8%
More
EPS
$-1.8
FCF per Share
$-0.4
Short interest
0.2%
Employees
34
Rev per Employee
$350.0k
Show more

Is LAVA Therapeutics NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

LAVA Therapeutics NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a LAVA Therapeutics NV forecast:

6x Buy
60%
4x Hold
40%

Analyst Opinions

10 Analysts have issued a LAVA Therapeutics NV forecast:

Buy
60%
Hold
40%

Financial data from LAVA Therapeutics NV

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
12 12
4% 4%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
91% 91%
188%
- Research and Development Expense 47 47
59% 59%
396%
-58 -58
91% 91%
-485%
- Depreciation and Amortization -0.14 -0.14
111% 111%
-1%
EBIT (Operating Income) EBIT -58 -58
83% 83%
-484%
Net Profit -49 -49
72% 72%
-411%

In millions USD.

Don't miss a Thing! We will send you all news about LAVA Therapeutics NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

LAVA Therapeutics NV Stock News

Neutral
GlobeNewsWire
10 days ago
UTRECHT, The Netherlands, and PHILADELPHIA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or the “Company”), a clinical-stage immuno-oncology company historically focused on its proprietary Gammabody® bispecific gamma delta T cell engagers, today announced financial results for the second quarter ended June 30, 2025 and provided a corporate update.
Neutral
PRNewsWire
16 days ago
NEW YORK , Aug. 8, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Steelcase Inc. (NYSE: SCS)'s  sale of HNI Corporation for $7.20 in cash and 0.2192 shares of HNI common stock for each share of Steelcase. If you ar...
Neutral
Business Wire
20 days ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LAVA Therapeutics N.V. (NASDAQ: LVTX) to XOMA Royalty Corporation is fair to LAVA shareholders. Under the terms of the proposed transaction, XOMA Royalty will acquire LAVA for $1.16 in cash per share, plus up to $0.08 per share and a non-transferable contingent value right per share re...
More LAVA Therapeutics NV News

Company Profile

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The firm develops next generation T-cell engaging bispecific antibodies to treat cancer. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.

Head office Netherlands
CEO Stephen Hurly
Employees 34
Founded 2016
Website www.lavatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today